SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Klareskog Lars)
 

Sökning: WFRF:(Klareskog Lars) > Risk and case chara...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006763naa a2200889 4500
001oai:DiVA.org:uu-103051
003SwePub
008090513s2005 | |||||||||||000 ||eng|
009oai:DiVA.org:umu-13362
009oai:lup.lub.lu.se:0a272b79-ec06-42cc-8ae7-95beedd6a8c1
009oai:prod.swepub.kib.ki.se:1948993
009oai:DiVA.org:liu-33261
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1030512 URI
0247 a https://doi.org/10.1002/art.211372 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-133622 URI
0247 a https://lup.lub.lu.se/record/2324132 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:19489932 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-332612 URI
040 a (SwePub)uud (SwePub)umud (SwePub)lud (SwePub)kid (SwePub)liu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Askling, Johanu Karolinska Institutet4 aut
2451 0a Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden
264 c 2005
264 1b Wiley,c 2005
338 a print2 rdacarrier
520 a OBJECTIVE:Because treatment with tumor necrosis factor (TNF) antagonists may increase the risk of tuberculosis (TB), and because knowledge of the risk of TB in rheumatoid arthritis (RA) not treated with biologics is scarce and of uncertain generalizability to low-risk populations, this study sought to determine the risk of TB among Swedish patients with RA.METHODS:Using data from Swedish nationwide and population-based registers and data from an ongoing monitoring program of TNF antagonists, the relative risks of TB in patients with RA (versus the general population) and of TB associated with TNF antagonists (versus RA patients not treated with biologics) were determined by comparing the incidence of hospitalization for TB in 3 RA cohorts and 2 general population cohorts from 1999 to 2001. We also reviewed the characteristics of all reported cases of TB in RA patients treated with TNF antagonists in Sweden and calculated the incidence of TB per type of TNF antagonist between 1999 and 2004.RESULTS:During 1999-2001, RA patients who were not treated with TNF antagonists were at increased risk of TB versus the general population (relative risk 2.0, 95% confidence interval [95% CI] 1.2-3.4). RA patients treated with TNF antagonists had a 4-fold increased risk of TB (relative risk 4.0, 95% CI 1.3-12) versus RA patients not treated with TNF antagonists. The reported TB cases during 1999-2004 in RA patients exposed to TNF antagonists (9 infliximab, 4 etanercept, 2 both) were predominantly pulmonary. TB occurred up to 3 years following the start of treatment.CONCLUSION:Irrespective of whether TNF antagonists are administered, Swedish patients with RA are at increased risk of TB. During 1999-2001, TNF antagonists were associated with an increased risk of TB, up to 4-fold in magnitude. This increased risk may persist over time during treatment and is related to both infliximab and etanercept.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reumatologi och inflammation0 (SwePub)302102 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Rheumatology and Autoimmunity0 (SwePub)302102 hsv//eng
653 a Adolescent
653 a Adult
653 a Adverse Drug Reaction Reporting Systems
653 a Aged
653 a Aged; 80 and over
653 a Antibodies; Monoclonal/*adverse effects/immunology
653 a Arthritis; Rheumatoid/*drug therapy/epidemiology/immunology
653 a Female
653 a Humans
653 a Immunosuppression
653 a Male
653 a Middle Aged
653 a Registries
653 a Research Support; Non-U.S. Gov't
653 a Risk Factors
653 a Sweden/epidemiology
653 a Tuberculosis; Pulmonary/epidemiology/*immunology
653 a Tumor Necrosis Factor-alpha/*antagonists & inhibitors/immunology
653 a MEDICINE
653 a MEDICIN
7001 a Fored, C. Michaelu Karolinska Institutet4 aut
7001 a Brandt, Lenau Karolinska Institutet4 aut
7001 a Baecklund, Evau Uppsala universitet,Reumatologi4 aut0 (Swepub:uu)evaba786
7001 a Bertilsson, Lennart4 aut
7001 a Cöster, Lars,d 1945-u Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Reumatologi,Länskliniken för Reumatologi i Östergötland4 aut0 (Swepub:liu)larco79
7001 a Geborek, Pierreu Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)reum-pge
7001 a Jacobsson, Lennartu Lund University,Lunds universitet,Internmedicin - epidemiologi,Forskargrupper vid Lunds universitet,Internal Medicine - Epidemiology,Lund University Research Groups4 aut0 (Swepub:lu)orto-lja
7001 a Lindblad, Staffanu Karolinska Institutet4 aut
7001 a Lysholm, Jörgen4 aut
7001 a Rantapää-Dahlqvist, Solbrittu Umeå universitet,Reumatologi4 aut0 (Swepub:umu)sora0001
7001 a Saxne, Toreu Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)reum-tsa
7001 a Romanus, Victoria4 aut
7001 a Klareskog, Larsu Karolinska Institutet4 aut
7001 a Feltelius, Nilsu Uppsala universitet,Institutionen för medicinska vetenskaper4 aut
7102 a Karolinska Institutetb Reumatologi4 org
7730 t Arthritis and Rheumatismd : Wileyg 52:7, s. 1986-1992q 52:7<1986-1992x 0004-3591x 1529-0131
8564 u http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=15986370&dopt=Citation
8564 u http://dx.doi.org/10.1002/art.21137y FULLTEXT
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-103051
8564 8u https://doi.org/10.1002/art.21137
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-13362
8564 8u https://lup.lub.lu.se/record/232413
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:1948993
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-33261

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy